Clinical Trials Logo
  1. Home
  2. T-Cell Lymphoma
  3. NCT00893516
  4. Details
NCT00893516 Clinical Trial

CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma

T-cell Lymphoma Clinical Trial

Official title:
A Multicentre Open-label Dose Escalation Tiral of Zanolimumab in Combination With CHOP Chemotherapy in Patients With CD4 Positive Non-cutaneous Peripheral T-cell Lymphoma With Nodal Involvement.

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00893516
Other study ID # GEN112
Secondary ID
Status Terminated
Phase Phase 2
First received
Last updated
Start date May 2007
Est. completion date December 2008

Study information
Verified date March 2024
Source Emergent BioSolutions
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Evaluation of CD4 in combination with CHO chemotherapy in subjects with nodal involvement of non cutaneous Tcell lymphoma.

Recruitment information / eligibility
Status Terminated
Enrollment 5
Est. completion date December 2008
Est. primary completion date October 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - study is closed to enrollment Exclusion Criteria: - study is closed to enrollment

Study Design

Related Conditions & MeSH terms

Intervention

Biological:
• CHOP + CD4

Drug:
• CHOP

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
Emergent BioSolutions

Outcome
Type Measure Description Time frame Safety issue
Primary Primary Outcome Unavailable All efforts to obtain data have been exhausted, therefore we have no data available to report.
See also
  Status Clinical Trial Phase
Completed NCT00959686 - Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma Phase 2
Active, not recruiting NCT04712864 - Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma Phase 1
Recruiting NCT05665530 - A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib in Participants With R/R Hematologic Malignancies Phase 1
Completed NCT01941680 - High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant
Recruiting NCT05075460 - Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma Phase 3
Completed NCT03734601 - Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation Phase 2
Completed NCT02017613 - Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies Phase 1
Enrolling by invitation NCT01854112 - Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma N/A
Completed NCT01553786 - Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) Phase 2
Completed NCT00542919 - A Study for Patients With Non-Hodgkin's Lymphomas Phase 2
Recruiting NCT06131801 - Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
Active, not recruiting NCT03952078 - A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma Phase 1
Not yet recruiting NCT05387226 - Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma Phase 1
Completed NCT02424045 - Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma Phase 2
Completed NCT01871675 - Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies Phase 1
Completed NCT01902225 - Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma Phase 1
Recruiting NCT02086591 - A Phase II Study of Doxycycline in Relapsed NHL Phase 2
Recruiting NCT04264078 - Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies Early Phase 1
Completed NCT00001582 - Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer
Completed NCT00322985 - A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma Phase 2